Thursday 28th November 2024 13:00 - 14:00 (GMT)
Joint HTA, combined with prospective changes to the EU general pharmaceutical legislation, will require companies to devote enormous time and resources to adapting to new procedures.
Are you up to speed?
Trying to meet the needs of the EU’s 27 Member States is likely to take precedence over a UK market that is at risk of being marginalised. The relative timing of EU vs UK marketing authorisation will also likely increase the challenges for the UK market.
Once the first JCA reports are published, it remains to be seen how they will be used in practice in EU Member States. The potential use of the reports in the UK and countries outside of Europe will also be one to watch, and highlighted by our experienced panel in this must-attend 60-minute masterclass for LSAA members.
28th Nov 2024 13:00 – 14:00 (GMT)